All In Biotech

NDA 206316 · Daiichi Sankyo INC

Savaysa

Edoxaban Tosylate · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Oct 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Jan 8, 2015

Approved uses

5

Original approval plus efficacy supplements

Registered trials

123

38 Phase 3, 19 recruiting

FAERS reports

6,825

6,132 serious, 899 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: (A) REDUCED EFFICACY IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS WITH CREATININE CLEARANCE (CRCL) > 95 ML/MIN (B) PREMATURE DISCONTINUATION OF SAVAYSA INCREASES THE RISK OF ISCHEMIC EVENTS (C) SPINAL/EPIDURAL HEMATOMA WARNING: (A) REDUCED EFFICACY IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS WITH CREATININE CLEARANCE (CRCL) > 95 ML/MIN (B) PREMATURE DISCONTINUATION OF SAVAYSA INCREASES THE RISK OF ISCHEMIC EVENTS (C) SPINAL/EPIDURAL HEMATOMA See full prescribing information for complete boxed warning. (A) REDUCED EFFICACY IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS WITH CRCL > 95 ML/MIN: SAVAYSA should not be used in patients with CrCL > 95 mL/min. In the ENGAGE AF-TIMI 48 study, nonvalvular atrial fibrillation patients with CrCL > 95 mL/min had an increased rate of ischemic stroke with SAVAYSA 60 mg once daily compared to patients treated with warfarin. In these patients...

What it is approved for

From the label in effect Jul 10, 2025.

SAVAYSA is a factor Xa inhibitor indicated: To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) ( 1.1 ) Limitation of Use for NVAF SAVAYSA should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg) ( 1.1 ) SAVAYSA is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant ( 1.2 ) 1.1 Reduction in the Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation SAVAYSA is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). Limitation of Use for NVAF SAVAYSA should not be used in patients with CrCL > 95 mL/min because of an increased risk of ischemic stroke compared to warfarin [see Dosage and Administration (2.1) , Warnings and Precautions (5.1) and Clinical Studies (14.1) ] . 1.2 Treatment of Deep Vein Thrombosis and Pulmonary Embolism SAVAYSA is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant.

Mechanism: Edoxaban is a selective inhibitor of FXa. It does not require antithrombin III for antithrombotic activity. Edoxaban inhibits free FXa, and prothrombinase activity and inhibits thrombin-induced platelet aggregation. Inhibition of FXa in the coagulation cascade reduces thrombin generation and reduces thrombus formation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • SAVAYSA · EDOXABAN TOSYLATE EQ 60MG BASE · TABLET, ORAL · Prescription
  • SAVAYSA · EDOXABAN TOSYLATE EQ 15MG BASE · TABLET, ORAL · Prescription
  • SAVAYSA · EDOXABAN TOSYLATE EQ 30MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Edoxaban" as an intervention, any sponsor and status, largest first.

All 123 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • anaemia329
  • off label use323
  • renal impairment295
  • dyspnoea274
  • cerebral infarction273
  • cardiac failure270
  • nausea247
  • atrial fibrillation226
  • pneumonia224
  • diarrhoea216
  • fall214
  • gastrointestinal haemorrhage207

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20101
2015345
2016253
2017130
201877
201996
2020119
2021569
20221,151
20231,178
20241,188
2025993
2026725

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Savaysa (Edoxaban Tosylate)

2024 spending

$5.1M

Beneficiaries

1,536

7,868 claims

Per beneficiary

$3,331

$13.81 per unit

View as table
YearSpending
2020$7,799,760
2021$6,659,333
2022$5,817,571
2023$5,343,976
2024$5,115,977

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 485 on PubMed

Sponsor: Daiichi Sankyo

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.